Results 161 to 170 of about 4,730,461 (228)

Clinical and Epidemiological Characteristics of Multiple Sclerosis in a Peruvian Cohort: A Retrospective Study Across Three Lima Hospitals. [PDF]

Neurol Int
Cruz AC, Perez-Villegas J, Alvarado E, Smith E, Dueñas-Pacheco I.   +4 more
europepmc   +1 more source

From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing-Remitting Multiple Sclerosis. [PDF]

J Clin Med
Yaşargün DÖ, Türkoğlu R.
europepmc   +1 more source

Dissociating Fatigue and Fatigability in Multiple Sclerosis: The Role of Cognitive Processing Speed

European Journal of Neurology, Volume 33, Issue 10, October 2026.
In people with multiple sclerosis, task‐induced fatigability normalized once cognitive load was calibrated to each patient's processing speed, whereas perceived fatigue remained elevated. Long‐term fatigue—but not fatigability—was associated with putamen and callosal atrophy, an association mediated by slowed processing speed, which emerges as a key ...
Jeromy Hrabovecky, Sophie Elands, Guillermo Borragán, Antonin Rovai, Nicolas Gaspard, Philippe Peigneux, Xavier De Tiège, Hichem Slama, Mélanie Strauss   +8 more
wiley   +1 more source

Patterns and predictors of transition between multiple sclerosis phenotypes: A longitudinal analysis. [PDF]

Mult Scler J Exp Transl Clin
Bose G, Greene N, Healy BC, Weiner HL, Farnett L, Higuchi K, Chitnis T.   +6 more
europepmc   +1 more source

Comparator Event Rates, Baseline Activity, and Operational Selection Pressure in Relapsing Multiple Sclerosis Trials: A Meta‐Epidemiological Analysis

European Journal of Neurology, Volume 33, Issue 10, October 2026.
Across 15 treated‐reference arms from nine phase 3 relapsing multiple sclerosis programs, reference‐arm relapse rates declined alongside baseline prior‐year relapse activity. A geography‐weighted Operational Selection Pressure Index, reflecting ocrelizumab approval maturity during recruitment, was associated with lower program‐level relapse rates but ...
Steffen Pfeuffer, Lars Masanneck, Marc Pawlitzki, Hans‐Peter Hartung   +3 more
wiley   +1 more source

Correlation Is Not Prediction: Reassessing Predictive MRI Evidence in Guidelines for Persons With Relapsing-Remitting Multiple Sclerosis. [PDF]

J Cent Nerv Syst Dis
Minas D, Buchka S, Havla J, Mansmann U.
europepmc   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Journal of Internal Medicine, Volume 300, Issue 4, Page 461-479, October 2026.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Nasal Mucociliary Clearance and Its Relationship With Disease Severity in Patients With Multiple Sclerosis. [PDF]

Med Sci Monit
Baydar C, Yalınkılıç A, Çetin YS.
europepmc   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, Volume 65, Issue 39, 21 September 2026.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Cognition in multiple sclerosis within the modern diagnostic and treatment era. [PDF]

Brain
Sumowski JF, Levy S, Katz Sand I, Brandstadter R, Dvorak E, Anderson J, Fabian MT, Graney RA, Lublin FD, Miller AE, Sandry J.   +10 more
europepmc   +1 more source